European Commission Approves Tesaro’s Zejula as Maintenance Therapy for Ovarian Cancer

European Commission Approves Tesaro’s Zejula as Maintenance Therapy for Ovarian Cancer
The European Commission has approved Tesaro‘s Zejula (niraparib) as a maintenance treatment for ovarian cancer, with or without BCRA mutations, in women who have shown a complete or partial response to platinum-based chemotherapy. The treatment was approved as a stand-alone therapy for adult patients with high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *